atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Sam Altman also said AI could already diagnose better than doctors, as his company expands into Washington. The OpenAI founder then turned to healthcare, making the suggestion that AI’s diagnostic capabilities had surpassed human doctors, but wouldn’t go so far as to accept…
Attendees
Sponsors and Exhibitors
Contact us